Key result
Vericiguat cuts CV death or HF hospitalization by ~13% vs placebo.
Why the study?
The efficacy of vericiguat was elusive for heart failure.
Does vericiguat reduce the composite outcome of cardiovascular death or heart failure hospitalization in patients with heart failure?
Meta-Analysis
Does vericiguat reduce the composite outcome of cardiovascular death or heart failure hospitalization in patients with heart failure?
In a meta-analysis of 4 RCTs, vericiguat significantly reduced the composite of cardiovascular death or heart failure hospitalization in patients with heart failure.
Supports vericiguat to reduce CV death or HF hospitalization in heart failure; extends prior RCT evidence via meta-analysis of 4 trials.
BACKGROUND: The efficacy of vericiguat was elusive for heart failure. This meta-analysis aimed to explore the efficacy of vericiguat for heart failure. METHODS: PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases have been searched through October 2022 and we included randomized controlled trials reporting the effect of vericiguat versus placebo in patients with heart failure. RESULTS: Four randomized controlled trials were included in the meta-analysis. Compared with placebo group for heart failure, vericiguat treatment was able to substantially improve the composite outcome of cardiovascular death or heart failure hospitalization (odds ratio [OR] = 0.87; 95% confidence interval [CI] = 0.78 to 0.97; P = .02), but unraveled no obvious impact on hospitalization for heart failure (OR = 0.89; 95% CI = 0.79 to 1.00; P = .05), death from cardiovascular causes (OR = 0.93; 95% CI = 0.77 to 1.13; P = .48), death from any cause (OR = 0.96; 95% CI = 0.84 to 1.10; P = .56), adverse events (OR = 0.95; 95% CI = 0.84 to 1.08; P = .42) or serious adverse events (OR = 0.92; 95% CI = 0.82 to 1.02; P = .12). CONCLUSIONS: Vericiguat treatment may benefit to treat heart failure.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2023) conducted a meta-analysis in heart failure. vericiguat vs. placebo was evaluated on composite outcome of cardiovascular death or heart failure hospitalization (OR 0.87, 95% CI 0.78 to 0.97, p=.02). Vericiguat treatment substantially improved the composite outcome of cardiovascular death or heart failure hospitalization compared with placebo (OR 0.87; 95% CI 0.78 to 0.97; P=.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: